Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:44 am
Author: Getaka|Social: XLinkedIn

Sun Pharma Advanced Research Company Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹19.83Overvalued by 83.48%vs CMP ₹120.00

P/E (15.0) × ROE (15.0%) × BV (₹10.80) × DY (2.00%)

Defaults: P/E=15, ROE=15%

₹12.24Overvalued by 89.80%vs CMP ₹120.00
MoS: -880.4% (Negative)Confidence: 50/100 (Moderate)Models: All 2: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹17.5963%Over (-85.3%)
Revenue MultipleRevenue₹3.3238%Over (-97.2%)
Consensus (2 models)₹12.24100%Overvalued

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -11.3% · Defaults: P/E=15, ROE=15%

*Investments are subject to market risks

Investment Snapshot

47
Sun Pharma Advanced Research Company Ltd scores 47/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health51/100 · Moderate
ROCE 298.0% ExcellentROE 0.0% WeakD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money60/100 · Moderate
FII holding up 0.59% (6mo) Slight increasePromoter holding at 65.7% Stable
Earnings Quality50/100 · Moderate
OPM contracting (-113% → -495%) DecliningWorking capital: -1,778 days (improving) Efficient
Quarterly Momentum25/100 · Weak
Revenue (4Q): -15% YoY DecliningOPM: -673.0% (down 174.0% YoY) Margin pressure
Industry Rank55/100 · Moderate
ROCE 298.0% vs industry 48.4% Above peers3Y sales CAGR: -19% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Sun Pharma Advanced Research Company Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
40/100
Moderate
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 0.0 vs Ind 271.4 | ROCE 298.0% | ROE 0.0% | CFO/NP N/A
Balance Sheet Stress
20/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.00x | IntCov 0.0x | Current 2.54x | Borrow/Reserve N/A
Cash Flow Reliability
86/100
Strong
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹-345 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII +0.28 pp | DII -0.27 pp | Prom 0.00 pp
Business Momentum
+100
Watch closely
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales 0.0% | Q NP -6.6% | Q OPM +165.0 pp
Derived FieldValueHow it is derived
Valuation Gap %-89.8%((Fair Value - CMP) / CMP) × 100
Borrowings / ReservesN/ALatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change+0.28 ppLatest FII% minus previous FII%
DII Change-0.27 ppLatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change+7,813Latest shareholder count minus previous count
Quarterly Sales Change0.0%Latest quarter sales vs previous quarter sales
Quarterly Profit Change-6.6%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change+165.0 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:44 am

Market Cap 3,905 Cr.
Current Price 120
Intrinsic Value₹12.24
High / Low 204/108
Stock P/E
Book Value 10.8
Dividend Yield0.00 %
ROCE298 %
ROE%
Face Value 1.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sun Pharma Advanced Research Company Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Sun Pharma Advanced Research Company Ltd 3,905 Cr. 120 204/108 10.80.00 %298 %% 1.00
Dredging Corporation of India Ltd 2,322 Cr. 829 1,246/495 4050.00 %0.31 %3.67 % 10.0
Logica Infoway Ltd 322 Cr. 181 267/16323.5 53.00.00 %14.3 %14.1 % 10.0
Syngene International Ltd 15,973 Cr. 396 761/38139.0 1180.32 %13.5 %10.5 % 10.0
Mipco Seamless Rings (Gujarat) Ltd 9.64 Cr. 26.9 37.4/22.0964 3.710.00 %%% 10.0
Industry Average5,630.50 Cr219.61271.38103.340.05%48.42%7.44%9.00

All Competitor Stocks of Sun Pharma Advanced Research Company Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1314824211417171315271088
Expenses 1151371261131161241121178981627465
Operating Profit 16-90-102-91-103-108-95-104-74-54-52-66-57
OPM % 12%-188%-427%-432%-740%-649%-566%-808%-499%-198%-543%-838%-673%
Other Income 01110864200090-12
Interest 3000011135689
Depreciation 3333333333333
Profit before tax 10-82-95-86-100-107-97-108-80-61-52-76-81
Tax % 0%0%0%0%0%0%0%0%0%0%0%0%0%
Net Profit 10-82-95-86-100-107-97-108-80-61-52-76-81
EPS in Rs 0.37-2.53-2.94-2.66-3.07-3.29-2.98-3.32-2.46-1.88-1.60-2.34-2.48

Last Updated: March 3, 2026, 2:30 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 12:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1671561611817818377253137239767253
Expenses 134191224304321334387388324453479399282
Operating Profit 34-35-63-123-243-151-310-135-187-214-404-327-229
OPM % 20%-23%-39%-68%-310%-83%-404%-53%-136%-90%-534%-456%-431%
Other Income 1033145414105711292-3
Interest 6022003111382927
Depreciation 4788889111012121110
Profit before tax 34-40-70-119-197-145-312-151-203-223-388-345-270
Tax % 12%0%0%0%0%0%0%0%0%0%0%0%
Net Profit 30-40-70-119-197-145-312-151-203-223-388-345-270
EPS in Rs 1.23-1.60-2.83-4.82-7.85-5.55-11.92-5.77-7.48-6.86-11.96-10.64-8.30
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-233.33%-75.00%-70.00%-65.55%26.40%-115.17%51.60%-34.44%-9.85%-73.99%11.08%
Change in YoY Net Profit Growth (%)0.00%158.33%5.00%4.45%91.94%-141.57%166.77%-86.04%24.58%-64.14%85.07%

Sun Pharma Advanced Research Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-7%
5 Years:-1%
3 Years:-19%
TTM:-6%
Compounded Profit Growth
10 Years:%
5 Years:-2%
3 Years:-30%
TTM:23%
Stock Price CAGR
10 Years:-9%
5 Years:-4%
3 Years:-14%
1 Year:-36%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:%

Last Updated: September 5, 2025, 1:36 pm

Balance Sheet

Last Updated: February 1, 2026, 1:59 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 24242425252626262732323232
Reserves 116768133160270-45-194448092-253-381
Borrowings 545632267236791656265417
Other Liabilities 393975111122101224162170302305284252
Total Liabilities 184143163273309398273230280830486329320
Fixed Assets 646770695258104919210610395162
CWIP 1011324325262744541
Investments 600101082118612291200
Other Assets 1127692192146106128127150406338179156
Total Assets 184143163273309398273230280830486329320

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 37-41-44-128-183-172-211-152-208-69-429-362
Cash from Investing Activity + 4453-13-7-105-1021552-29-548391158
Cash from Financing Activity + -81-1511942242745515922961743201
Net Cash Flow -011-760-63009-8-14-4
Free Cash Flow 33-49-56-136-200-184-264-153-233-84-455-372
CFO/OP 134%110%48%88%71%111%65%111%114%35%105%114%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow29.00-39.00-119.00-126.00-245.00-153.00-377.00-371.00-266.00-230.00-460.00-592.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 614721788220762574507582
Inventory Days 00000000
Days Payable
Cash Conversion Cycle 614721788220762574507582
Working Capital Days 12720-161-60-232-98-842-268-301-193-746-1,778
ROCE %21%-32%-71%-94%-143%-62%-183%-242%-218%-67%-109%-298%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 65.68%65.68%65.68%65.68%65.68%65.68%65.68%65.68%65.68%65.67%65.67%65.67%
FIIs 3.64%3.64%3.67%3.30%3.24%2.64%2.15%2.23%1.45%1.47%1.76%2.04%
DIIs 0.63%0.63%0.65%0.67%0.67%0.17%0.21%0.64%1.13%0.97%1.05%0.78%
Public 30.04%30.06%29.99%30.36%30.41%31.51%31.96%31.47%31.76%31.88%31.52%31.51%
No. of Shareholders 98,7771,00,8071,01,4331,03,9901,02,7431,25,1841,28,2051,31,0341,42,8641,40,7241,36,9971,44,810

Shareholding Pattern Chart

No. of Shareholders

Sun Pharma Advanced Research Company Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 2,413,308 0.45 30.672,133,2062026-02-23 00:52:0113.13%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23
FaceValue 1.001.001.00
Basic EPS (Rs.) -10.55-11.93-7.82
Diluted EPS (Rs.) -10.55-11.93-7.82
Cash EPS (Rs.) -10.17-11.55-6.50
Book Value[Excl.RevalReserv]/Share (Rs.) -6.683.8815.80
Book Value[Incl.RevalReserv]/Share (Rs.) -6.683.8815.80
Revenue From Operations / Share (Rs.) 2.212.337.36
PBDIT / Share (Rs.) -9.90-11.48-6.26
PBIT / Share (Rs.) -10.28-11.87-6.62
PBT / Share (Rs.) -10.56-11.92-6.86
Net Profit / Share (Rs.) -10.55-11.93-6.86
NP After MI And SOA / Share (Rs.) -10.55-11.93-6.86
PBDIT Margin (%) -447.77-493.24-85.09
PBIT Margin (%) -465.04-509.80-90.01
PBT Margin (%) -477.63-512.05-93.21
Net Profit Margin (%) -477.25-512.55-93.21
NP After MI And SOA Margin (%) -477.25-512.55-93.21
Return on Networth / Equity (%) 0.00-307.91-43.40
Return on Capital Employeed (%) 862.23-154.06-33.00
Return On Assets (%) -102.07-75.18-26.81
Long Term Debt / Equity (X) -0.460.000.00
Total Debt / Equity (X) -1.190.370.00
Asset Turnover Ratio (%) 0.160.110.00
Current Ratio (X) 0.071.022.54
Quick Ratio (X) 0.071.022.54
Interest Coverage Ratio (X) -35.55-219.89-26.61
Interest Coverage Ratio (Post Tax) (X) -36.89-227.50-28.15
Enterprise Value (Cr.) 5059.2711897.665712.17
EV / Net Operating Revenue (X) 70.50157.4923.92
EV / EBITDA (X) -15.74-31.93-28.11
MarketCap / Net Operating Revenue (X) 66.93158.9224.39
Price / BV (X) -22.1495.4711.36
Price / Net Operating Revenue (X) 66.93158.9324.39
EarningsYield -0.07-0.03-0.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Sun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L73100GJ2006PLC047837 and registration number is 047837. Currently Company is involved in the business activities of Research and experimental development on natural sciences and engineering. Company's Total Operating Revenue is Rs. 71.77 Cr. and Equity Capital is Rs. 32.45 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Medical Research ServicesPlot No. 5 & 6/1, Savli G.I.D.C. Estate, Savli - Vadodara Highway, Vadodra District Gujarat 391775Contact not found
Management
NamePosition Held
Mr. Dilip S ShanghviChairman & Non-Exe.Director
Dr. T RajamannarNon Executive Director
Ms. Vidhi ShanghviNon Executive Director
Mr. Venkateswarlu JastiIndependent Director
Ms. Bhavna DoshiIndependent Director
Dr. Ferzaan EngineerIndependent Director
Dr. Robert J SpiegelIndependent Director
Mrs. Rekha WarriarIndependent Director

FAQ

What is the intrinsic value of Sun Pharma Advanced Research Company Ltd and is it undervalued?

As of 05 April 2026, Sun Pharma Advanced Research Company Ltd's intrinsic value is ₹12.24, which is 89.80% lower than the current market price of ₹120.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (%), book value (₹10.8), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd is trading at ₹120.00 as of 05 April 2026, with a FY2026-2027 high of ₹204 and low of ₹108. The stock is currently near its 52-week low. Market cap stands at ₹3,905 Cr..

How does Sun Pharma Advanced Research Company Ltd's P/E ratio compare to its industry?

Sun Pharma Advanced Research Company Ltd has a P/E ratio of , which is below the industry average of 271.38. This is broadly in line with or below the industry average.

Is Sun Pharma Advanced Research Company Ltd financially healthy?

Key indicators for Sun Pharma Advanced Research Company Ltd: ROCE of 298 % indicates efficient capital utilization; ROE of % is below ideal levels (industry average: 7.44%). Dividend yield is 0.00 %.

Is Sun Pharma Advanced Research Company Ltd profitable and how is the profit trend?

Sun Pharma Advanced Research Company Ltd reported a net profit of ₹-345 Cr in Mar 2025 on revenue of ₹72 Cr. Compared to ₹-203 Cr in Mar 2022, the net profit shows a mixed trend.

Does Sun Pharma Advanced Research Company Ltd pay dividends?

Sun Pharma Advanced Research Company Ltd has a dividend yield of 0.00 % at the current price of ₹120.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sun Pharma Advanced Research Company Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports